JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266501

Human ZFR knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ZFR KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 131 bp deletion in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human ZFR knockout HEK-293T cell line (AB266501)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZFR knockout HEK-293T cell line (AB266501)

Homozygous : 131 bp deletion in exon4

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 131 bp deletion in exon 4

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266501-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266501 Human ZFR knockout HEK-293T cell line", "number":"AB266501-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266501-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266501-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266501 Human ZFR knockout HEK-293T cell line", "number":"AB266501-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266501-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266501-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266501 Human ZFR knockout HEK-293T cell line", "number":"AB266501-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266501-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266501 Human ZFR knockout HEK-293T cell line", "number":"AB266501-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ZFR
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The zinc finger RNA-binding protein commonly known as ZFR functions mechanically as an RNA-binding protein that plays a role in RNA processing and regulation. ZFR with a molecular mass of around 115 kDa contains zinc finger motifs that facilitate its binding to RNA. It is widely expressed across various tissues with significant expression in brain and muscle tissues. ZFR interacts specifically with RNA molecules to influence their stability and processing.
Biological function summary

ZFR regulates several processes related to RNA metabolism including splicing and degradation important for maintaining cellular RNA homeostasis. ZFR also participates as a subunit in larger ribonucleoprotein complexes which are essential for post-transcriptional gene regulation. Its activity in facilitating RNA transport and stability links it to essential cellular processes impacting gene expression at the post-transcriptional level.

Pathways

ZFR engages in regulatory networks that include pathways involved in RNA processing and stabilization. It plays a part in mRNA splicing pathways important for producing mature mRNA molecules from pre-mRNA. This interaction closely relates ZFR to other proteins such as SMN and other splicing factors integrating ZFR into broader gene expression and RNA management networks.

Alterations in ZFR expression or function have links to neurological conditions such as amyotrophic lateral sclerosis (ALS). This link is through the dysregulation of RNA-binding proteins like TDP-43 which ZFR connects with in RNA metabolic pathways affected in ALS. Additionally ZFR-related anomalies also show associations with certain muscular disorders due to its high expression in muscle and its role in RNA processing within these tissues.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com